Table 8.6a
Immunosuppression Use for Induction, 1996 to 2005
Recipients with Kidney-Pancreas Transplants

	Year of Transplant									
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005
Transplants	861	853	972	942	915	891	905	871	881	903
With Immunosuppression Info	861	850	969	936	907	887	899	861	861	887
Induction Drugs										
ALG	1.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	32.2%	36.8%	13.4%	6.3%	3.0%	2.6%	2.8%	1.9%	2.6%	2.4%
OKT3	52.3%	42.8%	27.8%	15.5%	8.2%	3.6%	1.2%	0.3%	0.8%	0.3%
Thymoglobulin	0.2%	0.1%	0.4%	8.8%	22.9%	28.7%	39.2%	48.8%	44.4%	51.2%
Zenapax	0.1%	0.4%	20.5%	27.0%	21.8%	20.0%	16.4%	8.4%	5.0%	4.5%
Simulect	0.1%	0.4%	8.5%	17.1%	27.1%	31.1%	26.4%	16.0%	12.4%	8.2%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	7.8%	18.5%	14.5%
No Induction Drugs Recorded	18.1%	25.5%	34.7%	33.8%	26.8%	24.4%	23.5%	20.8%	21.0%	21.9%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.